Notice Regarding Transfer of Distribution and Sales in Japan and Termination of Joint Promotion of SGLT2 Inhibitor “Forxiga® Tablets 5mg, 10mg”

Overview of Contract Termination

Ono Pharmaceutical Co., Ltd. has agreed to terminate the contract on March 31, 2026, with AstraZeneca K.K. and AstraZeneca UK Limited concerning the distribution, sales, and joint promotion of the selective SGLT2 inhibitor "Forxiga® Tablets 5mg, 10mg" in Japan, and to transfer distribution and sales to AstraZeneca. The contract was initially executed in December 2013, and since obtaining manufacturing and marketing approval in March 2014, Ono Pharmaceutical had been responsible for distribution and sales while both companies conducted promotional activities. However, reflecting changes in the market environment and following consultations, the decision to terminate the contract was made.

Future Outlook and Impact

Following the termination of the contract, Ono Pharmaceutical’s sales revenue from Forxiga will cease from April 1, 2026; however, the impact on the current fiscal year’s performance is expected to be minor. The annual sales forecast for fiscal 2026 is 80 billion yen, and with the introduction of generic drugs, the effect on operating income for fiscal 2027 is assumed to be limited. Detailed information will be disclosed at the financial results announcement for the fiscal year ending March 2026. Both companies will cooperate in the transfer process and continue to promote stable supply and appropriate use.